These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26960892)

  • 21. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What promise does PCSK9 hold?
    Kastelein JJ; Fouchier SW; Defesche JC
    J Am Coll Cardiol; 2005 May; 45(10):1620-1. PubMed ID: 15893177
    [No Abstract]   [Full Text] [Related]  

  • 24. PCSK9 inhibitors.
    Farnier M
    Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving the care of high-risk patients: the potential of PCSK9.
    Stock J
    Atherosclerosis; 2014 Feb; 232(2):420-2. PubMed ID: 24468158
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-shot, one cure with genome editing for dyslipidemia.
    Gupta RM
    Circ Cardiovasc Genet; 2014 Dec; 7(6):967-8. PubMed ID: 25516627
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
    Davidson MH
    J Clin Lipidol; 2013; 7(3 Suppl):S11-5. PubMed ID: 23642323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 34. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
    Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
    Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
    Grundy SM
    Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537
    [No Abstract]   [Full Text] [Related]  

  • 36. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond LDL cholesterol, a new role for PCSK9.
    Akram ON; Bernier A; Petrides F; Wong G; Lambert G
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
    [No Abstract]   [Full Text] [Related]  

  • 38. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.